Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Researchers at the University of Miami have identified a receptor called IL1RAP that helps pancreatic tumors resist treatment. By blocking it in preclinical studies, they disrupted the tumor's protective environment — reducing immune-suppressive cells and fibrosis while boosting cancer-fighting T cells. A first-of-its-kind clinical trial is now planned to test this approach alongside chemoimmunotherapy before surgery.
Pancreatic cancer is notoriously hard to treat, partly because tumors build a protective fortress of surrounding cells and tissue that shields them from chemotherapy and immunotherapy. Now, researchers at Sylvester Comprehensive Cancer Center (University of Miami) think they've found a key to dismantling that fortress: a receptor called IL1RAP.
IL1RAP acts as a shared "helper" receptor for multiple inflammatory signals, helping tumor cells, immune cells, and fibroblasts work together to resist treatment. In preclinical experiments, blocking IL1RAP disrupted this network — immune-suppressive cells became less abundant, cancer-fighting T cells became more active, and tumors developed less fibrosis and responded better to combination therapy. The findings were published in JCI Insight.
Based on these results, Sylvester is now launching a neoadjuvant clinical trial combining IL1RAP-targeted therapy with chemoimmunotherapy in patients with operable pancreatic cancer before surgery — a setup that will allow researchers to directly observe how tumors change in response to treatment.
Key Takeaways:
Why it matters: With pancreatic cancer survival rates still dismally low and newer KRAS-targeted therapies years away from reaching operable patients, IL1RAP inhibition offers a timely and potentially practice-changing strategy to improve outcomes for patients who can still undergo surgery.
